Altimmune Inc. Company Profile
NASDAQ: ALTHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 2.63 -1.13%
Altimmune at a glance
Altimmune Inc. (NASDAQ: ALT) is a Biotechnology company in the Healthcare sector headquartered in Gaithersburg, MD. Altimmune is led by Mr. Jerome Benedict Durso and employs about 57 people. At a market capitalization of $519.4 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001326190, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Altimmune do?
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Business description based on the company's public filings.
Company information
- Legal name
- Altimmune Inc.
- Ticker
- NASDAQ: ALT
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jerome Benedict Durso
- Employees
- 57
- Headquarters
- 910 Clopper Road, Gaithersburg, MD, United States
- Phone
- 240 654 1450
- Website
- altimmune.com
- Market cap
- $519.36M
- SEC CIK
- 0001326190
- Latest annual report
- 10-K · Mar 6, 2026
Companies similar to Altimmune
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MPLTMapLight Therapeutics Inc. | 9.36 | -3.41% | $520.19M | vs ALT |
| NGNENeurogene Inc. | 25.87 | +1.65% | $517.69M | vs ALT |
| OCSOculis Holding AG | 8.50 | -2.52% | $523.50M | vs ALT |
| EPRXEupraxia Pharmaceuticals Inc. | 7.78 | +0.52% | $514.05M | vs ALT |
| DRUGBright Minds Biosciences Inc. | 52.00 | +7.77% | $512.93M | vs ALT |
| BLSMBlossomHill Therapeutics Inc. | 16.61 | -3.93% | $527.95M | vs ALT |
| PBYIPuma Biotechnology Inc | 9.81 | +3.26% | $506.39M | vs ALT |
| RGNXREGENXBIO Inc. | 7.60 | +1.95% | $501.37M | vs ALT |